Drugs / ASP8062
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT04447287 | Jun → Nov 2020 | substance-related disorder | Astellas Pharma Global Development, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04003402 | Jul → Oct 2019 | — | Astellas Pharma Global Development, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03183739 | Jun → Oct 2017 | — | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT05096117 | Dec 2021 → Mar 2023 | alcohol-related disorders | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Completed | No outcome recorded |
| Phase 2 | NCT05062577 | Nov 2021 → Feb 2023 | substance-related disorder | Astellas Pharma Global Development, Inc. | Withdrawn | No outcome recorded |
| Phase 2 | NCT03092726 | May 2017 → Mar 2018 | fibromyalgia | Astellas Pharma Global Development, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASP8062 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05096117 ↗ |
| Action | Activate | “positive allosteric modulator activity on the γ-aminobutyric acid type B receptor” PMID 36738100 ↗ Feb 2023 |
| Route | Oral | “administered orally” NCT03092726 ↗ |